How much funding does Eunice and Milton Ring Grant for ROS1 Cancer Research provide?

The listing does not state a funding amount. Check the funder's announcement for specifics.

When is the deadline for Eunice and Milton Ring Grant for ROS1 Cancer Research?

The funder has not published a deadline for this grant.

Eunice and Milton Ring Grant for ROS1 Cancer Research

Q: How often is Eunice and Milton Ring Grant for ROS1 Cancer Research offered?

Eunice and Milton Ring Grant for ROS1 Cancer Research runs on an annual cycle.

The ROS1ders Inc

Foundation Annual Grants for Cancer Nonprofits Grants for Science Research

Funding Amount

Not stated

Deadline

Deadline not published

Grant Type

Foundation

Deadline history & next window

Cycle: Annual
Tracked since: April 2026

Source: the cycle recorded on this listing. Confirm dates with the funder.

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Other requirements

Applicants must hold a doctorate degree (PhD or MD, PhD preferred)
Must have faculty appointment at an academic or non-profit research institution

Overview

A seed grant for ROS1 cancer research. Funding is provided by Eunice and Milton Ring, whose daughter Karen Ring Weiss is a member of the ROS1+ cancer community.

Research Focus: Seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies

Geographic Scope: Not explicitly stated; appears to be open internationally

Eligibility Requirements:

Applicants must hold a doctorate degree (PhD or MD, PhD preferred)
Must have faculty appointment at an academic or non-profit research institution

Funder Information:

The ROS1ders, Inc.
1721 Eastern Avenue, Suite 19
Sacramento, CA 95864
Phone: +1 (916) 382-8544
Email: info@theros1ders.org
A 501(c)(3) nonprofit corporation (EIN 83-4490547)

Background: This grant is the third in a series of seed grants focused on ROS1+ cancers. The 2024 recipient was Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital, whose team is seeking to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors to overcome acquired resistance.